LBA20_PR - gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
| Autor: | Van Cutsem, E., Yoshino, T., Lenz, H.-J., Lonardi, S., Falcone, A., Limon, M.L., Saunders, M.P., Sobrero, A., Maiello, E., Park, Y.S., Monteagudo, R. Ferreiro, Hong, Y.S., Tomasek, J., Taniguchi, H., Ciardiello, F., Hocke, J., Oum'hamed, Z., Vlassak, S., Studeny, M., Tabernero, J. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi559-vi559 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|